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We have synthesized many amphoteric compounds through zwitter-ionization of classical tricyclic and basic antihistamines by conversion of N-alkyl groups into N alkylenecarboxy groups to develop non-sedative antialler gic agents with potent antihistaminic activities (1-6). Our investigations of the potencies of these compounds as well as their depressant effects on the central nervous system (CNS) showed that the combination of zwitter-ionization and introduction of a pyridine component into the tri cyclic antihistamines is important for attaining higher hydrophilicity, which is considered to be one of the fac tors reducing penetration into the CNS (6). Our efforts finally led to a new amphoteric compound, 11 dihydrobenz[b] oxepino [4,3 -b] pyridin l1-ylidene)piperidino]propionic acid dihydrate) ( Fig. 1) (6). Various pharmacological studies using mice, rats, guinea pigs and dogs have shown that HSR-609 has potent antiallergic and antihistaminic activities in vivo (6, 7). HSR-609 had high affinity only for histamine H1 receptors and low affinity for muscarinic and serotonin 9) . HSR-609 displayed poor ability to penetrate into the CNS in mice and guinea pigs due to its amphoteric chemical structure as determined by the ex vivo displacement of [3H]mepyramine binding to H1 receptors (6, 8, 9) . As details of the effects of HSR-609 on the CNS had not yet been examined, we conducted various behavioral analyses with mice and electroencephalographic (EEG) analysis with rabbits to directly evaluate its effects on brain electrical activity. We then tried to evaluate the pharmacological difference and/or similarity on the CNS effects under the same experimental conditions for HSR 609 and various typical sedative antiallergic agents, such as cyproheptadine hydrochloride, ketotifen fumarate, azelastine hydrochloride and oxatomide, and also the non-sedative antiallergic agent terfenadine (10 14). Fur thermore, we also tried to determine if the amphoteric chemical structure of HSR-609 is related to its lesser CNS effects, by comparing it with the non-amphoteric basic compound PY-608 (8-fluoro-5,11-dihydro-l l-(1-methyl 4-piperidylidene)benz [b] oxepino [4,3-b] pyridine), which has a similar chemical structure (Fig. 1) .
MATERIALS AND METHODS

Animals
Male ICR mice (Charles River, Kanagawa) and male Japanese White rabbits (Kitayama Labes, Kyoto) were used. The animals were fasted for more than 16 hr before oral administration of the test compounds.
Effect on general behavior in mice
Mice (5-week-old) in groups of 4 animals each were used. Each mouse was put in a transparent plastic cage (W: 170 x D: 235 X H: 125 mm). The general behavior of each animal was observed at 0.5, 1, 2, 4, 6, 8 and 24 hr after oral administration of the test compounds according to the method of Irwin (15). Food and water were given 8 hr after the administration.
Effect on spontaneous locomotor activity in mice Mice (5-week-old) in groups of 10 animals each were used. After oral administration of the test compounds, each mouse was immediately put into a transparent plastic cage (W: 295 x D: 345 x H: 175 mm). The sponta neous locomotor activity was measured continuously for 4 hr after the administration using SCANET (MV-10; Toyo Sangyo, Toyama), with a sensor of near infrared rays (870 nm) installed at 6-mm intervals at a height of 37.5 mm, and accumulated at 30-min intervals.
Effect on hexobarbital-induced sleeping time in mice Mice (5-week-old) in groups of 10 animals each were used. Mice were orally administered the test compounds and then were injected with hexobarbital (80 mg/kg, i.p.) 1 hr later. The sleeping time was measured from the time of loss to restoration of the righting reflex. The ID50 values and their 95% confidence limits were calculated from the number of animals showing more than 50% in hibition at each dose by comparison with the mean sleep ing time of the vehicle control according to the method of Tallarida and Murray (16).
Effect on reserpine-induced hypothermia in mice Mice (5-week-old) in groups of 8 animals each were used. The mice were injected with reserpine (2 mg/kg, s.c.), and then were made to fast. After 18 hr, the test compounds were administered orally. The rectal tempera ture was measured with a thermometer (BAT-12; Phys itemp Instruments, Clifton, NJ, USA) before and 0.5, 1, 2 and 4 hr after the administration.
Effect on spontaneous EEG, gross behavior and heart rate in rabbits Preparation of chronic animals with indwelling brain electrodes: Under pentobarbital sodium anesthesia (35 mg/kg, i.v.), rabbits (2.5 3.4 kg) were fixed on a univer sal stereotaxic instrument (Summit Medical, Tokyo), and EEG electrodes were implanted according to the method of Yamamoto et al. (17) . Bipolar silver ball electrodes (0.5 -1.0 mm diameter, 2 3 mm apart) were placed on the epidural surface of the frontal cortex (FC) of the animals. Bipolar stainless-steel electrodes (0.25 mm di ameter, 0.5 mm apart) insulated except for the tip of 0.5 mm (OKY91-042; Unique Medical, Tokyo) were inserted stereotaxically into the left amygdala (AMY: A; 2, L; 6, H; -6) and the left hippocampus (HIP: P; 2, L; 4, H; + 5) according to the brain atlas of Sawyer et al. for rab bits (18). Each electrode was soldered to a rectangular connector (HDAB-15; Hirose Denki, Tokyo), secured to the skull and fixed with dental cement (Yata Polyset; Yata Chemical, Osaka). A recovery period of at least 2 weeks was allowed before the start of experiments. The animal was given penicillin G potassium (5 x 104 units, s.c.) prophylactically to reduce infection. Polygraphic recording of EEG: The polygraphic recording was always carried out with an unanesthetized and unrestrained rabbit placed in a soundproof and elec trically shielded room after the animal was sufficiently accustomed to the experimental environment. The EEG polygram, consisting of EEG, electromyogram (EMG) of the posterior neck muscle, and Lead II electrocardiogram (heart rate), was recorded on an electroencephalograph (EEG-5414; Nihon Kohden, Tokyo) and also on a mag netic tape recorder (A-69; Sony, Tokyo) for subsequent computer analysis of the EEG. After the control obser vation of behavior and EEG polygram for 1 hr, the test compound was administered orally to the animal. Recording of the EEG polygram usually started at 10 o'clock and continued for 7 hr. Behavior changes were observed macroscopically. The results were compared with those of the same animal given the vehicle only. Different test compounds were administered to the same animal after an interval of at least 10 days.
Gross behavior, EEG pattern and sleep-wakefulness cycles: The observation of gross behavior and evaluation of EEG pattern were performed by the method of Yamamoto et al. (17) . The EEG recordings were visually classified into the following five stages: awake, rest, slow wave light sleep (SWLS), slow wave deep sleep (SWDS) and rapid eye movement sleep (REMS). The diagram matic representation of continuous changing of EEG levels is called the EEG sleep-wakefulness cycle (poly somnogram). The accumulated times of each EEG level for the initial 4 hr and each sleep-wakefulness cycle for 7 hr after the administration were compared with those of the vehicle control.
EEG power spectral analysis: Using an ATAC-450 sys tem (Nihon Kohden), EEG power spectra were derived from the magnetically recorded EEG during the initial 4 hr after the test compound administration. The EEG was converted into a digital value with a resolution of 10 bits per 9.76 msec and processed by Fast Fourier Transfor mation. Each segment of the power spectral density for 30 sec in the frequency range of 0-30 Hz with a resolu tion of 0.4 Hz was added to obtain one power spectrum. The continuous plotted EEG power spectra, called the EEG power spectral array (17), was recorded on an XY plotter (7475A; Hewlett Packard, San Diego, CA, USA). The power spectra was classified into four frequency bands defined as 5 (1.2-3.61-1z), 0 (4.0-7.6 Hz), a (8.0-12.8 Hz) and (3 (13.2-29.6 Hz). The individual and total frequencies of the power spectra were obtained from the initial 4 hr after the administration, and the relative potency of the power spectra was calculated in compari son with that of the vehicle control.
Drugs
The following agents were purchased: cyproheptadine (cyproheptadine hydrochloride; Pharmaceutia, Milan, Italy); ketotifen (ketotifen fumarate; Orion Chemicals, Espoo, Finland); terfenadine and imipramine (imipra mine hydrochloride) (Sigma Chemical, St. Louis, MO, USA); scopolamine (scopolamine hydrobromide) and hexobarbital (Tokyo Kasei Kogyo, Tokyo); reserpine (Apoplon; Daiichi Pharmaceutical, Tokyo); pentobar bital sodium (Nembutal injection; Dainippon Phar maceutical, Osaka); and penicillin G potassium (Meiji Seika, Tokyo). HSR-609, PY-608, azelastine (azelastine hydrochloride) and oxatomide were synthesized at the Research and Development Division, Hokuriku Seiyaku Co., Ltd. HSR-609, PY-608, cyproheptadine, oxatomide and terfenadine were suspended in 5 % gum arabic, while ketotifen, azelastine, imipramine and scopolamine were dissolved in distilled water; all of the agents were ad ministered orally. Effect on spontaneous locomotor activity in mice HSR-609 at doses of 10-300 mg/kg displayed no effect on spontaneous locomotor activity in mice during 4 hr after the oral administration (Fig. 2) . On the other hand, the activity increased for the initial 0.5 hr after the ad ministration with PY-608 at doses of 3 -10 mg/kg, for 0.5 -1.5 hr with cyproheptadine at 10 mg/kg, for 2 4 hr with oxatomide at 100 and 300 mg/kg (data not shown) and for 0.5 -1.5 hr with scopolamine at doses of 3 and 10 mg/kg. The activity decreased for the initial 0.5 1.5 hr after administration of PY-608 at a dose of 100 mg/kg, for 0.5 3.5 hr with cyproheptadine, for 0.5 -1 hr ketotifen at 100 mg/kg, for 0.5 4 hr with azelastine at 30 -100 mg/kg (data not shown) and 1.5 2 hr with terfenadine at 300 mg/kg. Effect on hexobarbital-induced sleeping time in mice One hour after oral administration of HSR-609 at doses of 10-300 mg/kg, there was no effect on the hexo barbital-induced sleeping time in mice, and the ID50 value was > 300 mg/kg (Fig. 3) . On the other hand, the sleeping time was prolonged by PY-608, cyproheptadine, ketotifen and terfenadine at doses of more than 30 mg/kg. It was also prolonged by azelastine and ox atomide at doses of more than 100 mg/kg (data not shown). The ID50 values (95% confidence limits) of PY 608, cyproheptadine, ketotifen, azelastine, oxatomide and terfenadine were 14 mg/kg (4.9-41 mg/kg), 4.4 mg/kg (1.4-14 mg/kg), 21 mg/kg (13-35 mg/kg), 18 mg/kg (4.8 71 mg/kg), 41 mg/kg (18 94 mg/kg) and 72 mg/kg (27 190 mg/kg), respectively. Scopolamine at doses of 3 30 mg/kg had no effect on hexobarbital induced sleeping time. Effect on reserpine-induced hypothermia in mice
The rectal temperature in mice in each group ranged from 36.9±0.2 to 38.0±0.3 C, but 18 hr after the injec tion of reserpine, it had fallen to 29.7:E0.5 to 31.3 -±:0.7C. HSR-609 at doses of 10 300 mg/kg did not show any influence on reserpine-induced hypothermia in comparison with that of the vehicle control (Fig. 4) . On the other hand, the hypothermia was reversed with PY 608 at doses of 0.3 -10 mg/kg, cyproheptadine at 3 and 10 mg/kg, ketotifen at 30 and 100 mg/kg, oxatomide at 30-300 mg/kg (data not shown) and imipramine at doses of 10 and 30 mg/kg. Azelastine at doses of 3-30 mg/kg (data not shown) and terfenadine at 30-300 mg/kg had no effect on the hypothermia.
Effect on spontaneous EEG, gross behavior and heart rate in rabbits EEG pattern, gross behavior and heart rate: The effects on spontaneous EEG and gross behavior in unanesthe tized and unrestrained rabbits with chronically indwelling brain electrodes were observed after oral administration of HSR-609, PY-608 and typical antiallergic agents. HSR-609 at doses of 10 and 100 mg/kg had no effect on EEG pattern, heart rate and gross behavior during the awake, rest, SWLS, SWDS and REMS episodes (Fig. 5 ).
Ketotifen at a dose of 30 mg/kg and terfenadine at 100 mg/kg also had no effect on these parameters (data not shown). On the other hand, cyproheptadine at a dose of 30 mg/kg caused marked high amplitude slow waves of all EEG leads, particularly in the AMY lead, and depres sion of gross behavior (Fig. 6 ). These changes were also observed with PY-608 at a dose of 30 mg/kg and scopolamine at a dose of 10 mg/kg (data not shown). The heart rate for the vehicle control ranged from about 120 to 240 beats/min, while PY-608 at a dose of 30 mg/kg in creased it in two of five rabbits, and the maximum value reached 310 beats/min. Cyproheptadine at a dose of 30 mg/kg increased the heart rate in two of five animals, and the maximum value reached 290 beats/min. Scopolamine also increased heart rate in three of five animals, and the maximum value reached 290 beats/min. periodic appearance of awake, rest, SWLS, SWDS and REMS episodes. No marked differences were seen in the sleep-wakefulness cycles between HSR-609 and the vehi cle control for 7 hr after administration (Fig. 7) . On the other hand, PY-608 and cyproheptadine at 30 mg/kg continuously and markedly increased the duration of SWDS and decreased the duration of awake, rest and REMS (Figs. 8 and 9 ). HSR-609 at a dose of 100 mg/kg had no obvious effect on the power spectral array of all EEG leads in comparison with that of the vehicle control (Fig. 10) . These results corresponded to previously described results of visual evaluation of EEG pattern and sleep-wakefulness cycles.
On the other hand, PY-608 at a dose of 30 mg/kg con tinuously and markedly enhanced the power spectra at low frequency bands (o and 0) in all EEG leads (Fig. 11) . These changes were also observed with cyproheptadine at a dose of 30 mg/kg and scopolamine at a dose of 10 mg/kg (data not shown). Table 2 presents the relative changes of each EEG power spectra at four frequency bands (6, 8, a and ;3) in the FC, which is said to be a typical indication of con scious levels, during 4 hr after administration of the test compounds in comparison with those of the vehicle con trols. HSR-609 and terfenadine at a dose of 100 mg/kg had no effect on the power spectra at each frequency band. On the other hand, PY-608, cyproheptadine and ketotifen at a dose of 30 mg/kg and scopolamine at a dose of 10 mg/kg enhanced the power spectra at the low frequency bands (o and 0) accompanied by an increase in the total frequency bands. As shown above, high ampli tude slow waves of the EEG after administration of these agents was also confirmed by analysis of the EEG power spectra. Change of each EEG power spectra were calculated by comparison with the mean response of the vehicle control, and the value represents the mean±S.E. of 5 rabbits. *P<0.05, **P<0.01, as compared with the vehicle control (paired Student's t-test).
DISCUSSION
In spite of the well-known depressant effects of sedative antiallergic agents and antihistamines on the CNS in hu mans, there have been few definite reports on systematic and comparative evaluation of the CNS effects of these agents using representative pharmacological methods such as general behavior, spontaneous locomotor activ ity, barbiturate-induced sleeping time and spontaneous EEG. Furthermore, some antihistamines such as diphen hydramine have both stimulant and depressant effects on the CNS, leading to different results with fine differences in experimental conditions, doses or route of administra tion (19, 20) . Therefore, we considered what kind of pharmacological experimental methods would be the most suitable for objectively evaluating the CNS effects of antiallergic agents having antihistaminic effects. This led us to try to clarify the pharmacological characteristics of HSR-609 on the CNS in comparison with typical sedative and non-sedative antiallergic agents having antihistaminic effects under the same experimental conditions, using methods typically employed for behavioral analysis in mice and EEG analysis in unanesthetized and unrestrain ed rabbits with chronically indwelling brain electrodes.
The experimental results obtained from behavioral analysis with ICR mice are summarized in Table 3 . HSR 609 displayed no effect on all spontaneous and induced behaviors. However, most of the sedative antiallergic agents showed stimulant and/or depressant effects on the general behavior and spontaneous locomotor activity, increased the hexobarbital-induced sleeping time and caused antagonistic effects on reserpine-induced hypo thermia in mice. Our results using ICR mice also show ed that cyproheptadine at low doses and oxatomide at high doses increased the spontaneous locomotor activity, in spite of cyproheptadine, ketotifen and azelastine at high doses decreasing it. Cyproheptadine was reported to have high affinity for muscarinic receptors in addition to high affinity for H1-receptors (9, 21). As scopolamine in creased spontaneous locomotor activity in the mice, one of the reasons that cyproheptadine also increase it may be due to its antimuscarinic activity. Furthermore, all the tested sedative antiallergic agents prolonged hexobar bital-induced sleeping time, in agreement with previous reports (2, 20, 22) . As in the case of imipramine, cypro heptadine and ketotifen showed antagonistic effects on reserpine-induced hypothermia, in agreement with previ ous reports (22, 23) . This is the first evidence that ox atomide at high doses causes effects similar to these other agents. The sedative antiallergic agents having antihista minic activity are known to cause sedative and stimulative side effects such as sedation, hypnosis, restlessness, insomnia, dizziness and headache at therapeutic doses (10) (11) (12) (13) (14) . These findings indicated that most of the sedative antiallergic agents displayed depressant and/or stimulant effects in mice, and these effects seem to well reflect their clinical sedative and/or stimulant effects in humans. These side effects on the CNS may be due to the properties of their antimuscarinic and/or imipramine mimetic monoaminergic activities in addition to their antihistaminic activities.
Interestingly, terfenadine at doses of more than 30 mg/kg prolonged the hexobarbital-induced sleeping time and decreased the spontaneous locomotor activity at a dose of 300 mg/kg. As for the case of ddY mice, terfena dine has been reported to have no effect on the sleeping time induced by hexobarbital (50 mg/kg, i.p.) (24) or to prolong it (80 mg/kg, i.p.) (2). The latter results agreed with ours observed under the same experimental condi tions with ICR mice. Terfenadine has been reported to be metabolized quickly and completely by hepatic cyto chrome P450. However, it accumulates when given in overdose, used with hepatic compromise, or when given with cytochrome P450 inhibitors such as ketoconazole and erythromycin (25). Barbiturates are also well-known to interact with hepatic cytochrome P450 (26). Therefore, terfenadine may have prolonged the sleeping time from lower doses due to a metabolic interaction between it and hexobarbital. These findings seem to indicate that the evaluation using behavioral analysis in mice did not correctly reflect the absence of clinical CNS effects of terfenadine. These findings also warn us that a different evaluation might result between clinical and pharma cological effects on the CNS if the judgment is done with only a few pharmacological methods limited to small animals. Table 4 . HSR-609 even at the higher dose of 100 mg/kg had no effect on the EEG pattern, sleep-wakefulness cycles, gross behavior and heart rate. An absence of the CNS effect of HSR-609 was also confirmed objectively by EEG power spectral analysis. In previous studies, HSR-609 showed a potent antihistaminic effect against histamine-induced increase of the vascular permeability in mice at doses of more than 0.03 mg/kg, and the effect was stronger than those of cyproheptadine, ketotifen, azelastine, oxatomide and terfenadine (6, 9). In spite of the potent antihista minic effect in mice, HSR-609 displayed no CNS effect on the behavior in mice and the EEG in rabbits. Terfenadine also showed no depressant effect on the CNS using EEG analysis, in agreement with previous reports in which it had no effect on the EEG in cats (27, 28) . These findings with terfenadine on the EEG should correspond to the absence of its clinical CNS effect, and it should be the same in the case of HSR-609. On the other hand, cypro heptadine and ketotifen caused slowing of the EEG, a continuous increase in the duration of SWDS, enhance ment of the EEG power spectra at low frequency bands such as 6 and 0, and depressant behavior. These results seem to agree with previous reports of ketotifen in creasing the duration of slow wave sleep and the 5 power spectra in cats and rats (20, 27) . The slowing effect of cyproheptadine on the EEG in rabbits was more potent than that of ketotifen. Cyproheptadine decreased the du ration of REMS and increased heart rate. Cyprohepta dine and ketotifen have been reported to have high affin ity for H1-receptors, while cyproheptadine also has higher affinity for muscarinic receptors than ketotifen (9, 21).
Our results with rabbits showed that scopolamine also causes slowing of EEG and decrease of the duration of REMS associated with an increase of heart rate, as reported previously for atropine (29, 30) . Many en dogenous sleep modulators and sleep substances have been reported (30). Among them, acetylcholine has been nominated as one of the most persuasive endogenous sleep substances regulating activation of EEG and the appearance of REMS episode (31, 32). Thus, the slowing of EEG and inhibition of REMS episode with cypro heptadine should result from its antimuscarinic activity in addition to antihistaminic activity. This hypothesis is supported by the report of an increase in the duration of SWDS, but no change in the REMS episode after a decrease of histamine content in the posterior hypo thalamic activating system of the cat due to local and/or systemic administration of a-fluoromethylhistidine, a histidine decarboxylase inhibitor (33).
The non-amphoteric basic compound PY-608 appeared to cause excitement behavior in mice such as restlessness, increase of spontaneous locomotor activity, antagonistic effects on reserpine-induced hypothermia, similar to im ipramine at low doses, and tremor and clonic convulsions at high doses. However, PY-608 caused depressant effects such as potentiation of hexobarbital-induced sleep at low doses and decrease of spontaneous locomotor activity at high doses. PY-608 caused slowing of EEG associated with an increase of heart rate, decrease of the duration of REMS and an enhancing of EEG power spectra at low frequency bands in rabbits similar to those of cyprohep tadine. These findings seem to indicate that PY-608 has both stimulant and depressant effects on behavior in mice, but only has a depressant effect on the EEG in rabbits. PY-608 has been shown to have high affinity for both H1 and muscarinic receptors (9). Therefore, these stimulant and depressant effects of PY-608 on the CNS may be due to its antimuscarinic and imipramine mimetic monoaminergic activities in addition to antihistaminic ac tivities, similar to those of cyproheptadine. As we previ ously reported, HSR-609 has been shown to have poor ability to penetrate into the CNS in mice and guinea pigs and high selectivity for the H1-receptor, which may be due to its amphoteric chemical structure (6, 9). The fine differences of chemical structure between HSR-609 and PY-608 appeared as obvious differences in their pharma cological effects on the CNS in mice and rabbits.
In conclusion, these findings suggest that if a new anti allergic agent is thought to have a correct effect on the CNS, integrated synthetic evaluation such as direct inves tigation of brain electrical activity should be conducted in addition to pharmacological behavioral analysis in mice.
HSR-609 appears to have no effect on the CNS from behavior analysis in mice and EEG analysis in rabbits, which may be due to its amphoteric chemical structure.
A part of these findings was presented at The 69th Annual Meeting of The Japanese Pharmacological Society in Nagasaki (March 20-23, 1996 ) (P-131).
